Globus Medical Inc GMED
We take great care to ensure that the data presented and summarized in this overview for GLOBUS MEDICAL INC is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding GMED
View all-
Vanguard Group Inc Valley Forge, PA11MShares$738 Million0.01% of portfolio
-
Black Rock Inc. New York, NY10.9MShares$734 Million0.01% of portfolio
-
Janus Henderson Group PLC London, X07.66MShares$517 Million0.23% of portfolio
-
State Street Corp Boston, MA3.58MShares$241 Million0.01% of portfolio
-
Wellington Management Group LLP Boston, MA3.25MShares$219 Million0.03% of portfolio
-
Champlain Investment Partners, LLC Burlington, VT2.5MShares$169 Million0.79% of portfolio
-
Camber Capital Management LP Boston, MA2.5MShares$169 Million3.29% of portfolio
-
Burgundy Asset Management Ltd. Toronto, A62.48MShares$167 Million1.42% of portfolio
-
Hawk Ridge Capital Management LP Los Angeles, CA2.37MShares$160 Million6.12% of portfolio
-
William Blair Investment Management, LLC Chicago, IL2.24MShares$151 Million0.32% of portfolio
Latest Institutional Activity in GMED
Top Purchases
Top Sells
About GMED
Globus Medical, Inc., a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. It offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative, deformity, tumors, and trauma conditions; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional pain management solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives. The company also offers products for the treatment of orthopedic trauma, including fracture plates, compression screws, intramedullary nails, and external fixation systems; and hip and knee joint solutions, including modular hip stems and acetabular cups, as well as posterior stabilizing and cruciate retaining knee arthroplasty implants. In addition, it distributes human cell, tissue, and cellular and tissue-based products. Globus Medical, Inc. was incorporated in 2003 and is headquartered in Audubon, Pennsylvania.
Insider Transactions at GMED
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
May 10
2024
|
Dan Lemaitre |
SELL
Open market or private sale
|
Direct |
63,300
-100.0%
|
$4,051,200
$64.61 P/Share
|
May 10
2024
|
Dan Lemaitre |
BUY
Exercise of conversion of derivative security
|
Direct |
52,500
+29.17%
|
$2,415,000
$46.87 P/Share
|
May 08
2024
|
David D Davidar |
SELL
Open market or private sale
|
Direct |
20,000
-3.41%
|
$1,300,000
$65.0 P/Share
|
Mar 15
2024
|
Leslie V Norwalk |
SELL
Open market or private sale
|
Direct |
10,590
-37.81%
|
$540,090
$51.99 P/Share
|
Mar 01
2024
|
Kelly Huller SVP, GC, Corporate Secretary |
SELL
Open market or private sale
|
Direct |
7,500
-79.23%
|
$405,000
$54.16 P/Share
|
Mar 01
2024
|
Kelly Huller SVP, GC, Corporate Secretary |
BUY
Exercise of conversion of derivative security
|
Direct |
7,500
+50.0%
|
$180,000
$24.9 P/Share
|
Jan 18
2024
|
David D Davidar |
SELL
Bona fide gift
|
Direct |
8,000
-1.35%
|
-
|
Sep 01
2023
|
Leslie V Norwalk |
BUY
Grant, award, or other acquisition
|
Direct |
28,009
+48.92%
|
-
|
Sep 01
2023
|
Dan Wolterman |
BUY
Grant, award, or other acquisition
|
Direct |
24,025
+50.0%
|
-
|
Sep 01
2023
|
John A De Ford |
BUY
Grant, award, or other acquisition
|
Direct |
15,578
+50.0%
|
-
|
May 15
2023
|
Dan Lemaitre |
SELL
Open market or private sale
|
Direct |
43,450
-80.09%
|
$2,433,200
$56.98 P/Share
|
May 15
2023
|
Dan Lemaitre |
BUY
Exercise of conversion of derivative security
|
Direct |
43,450
+23.53%
|
$1,042,800
$24.96 P/Share
|
Feb 09
2023
|
Dan Lemaitre |
BUY
Exercise of conversion of derivative security
|
Direct |
5,550
+33.95%
|
$127,650
$23.95 P/Share
|
Feb 02
2023
|
Keith W Pfeil SVP, Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
29,167
-100.0%
|
$2,245,859
$77.57 P/Share
|
Feb 02
2023
|
Keith W Pfeil SVP, Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
29,167
+41.98%
|
$1,487,517
$51.46 P/Share
|
Jan 27
2023
|
Ann D Rhoads |
BUY
Exercise of conversion of derivative security
|
Direct |
7,500
+24.68%
|
$90,000
$12.59 P/Share
|
Jan 27
2023
|
Dan Lemaitre |
BUY
Exercise of conversion of derivative security
|
Direct |
5,250
+50.0%
|
$63,000
$12.59 P/Share
|
Dec 01
2022
|
Kelly Huller SVP, GC, Corporate Secretary |
SELL
Open market or private sale
|
Direct |
7,500
-100.0%
|
$562,500
$75.0 P/Share
|
Dec 01
2022
|
Kelly Huller SVP, GC, Corporate Secretary |
BUY
Exercise of conversion of derivative security
|
Direct |
7,500
+50.0%
|
$90,000
$12.59 P/Share
|
Apr 19
2022
|
David D Davidar |
SELL
Open market or private sale
|
Direct |
31,500
-4.98%
|
$2,457,000
$78.03 P/Share
|
Last 12 Months Summary
Grant, award, or other acquisition | 67.6K shares |
---|---|
Exercise of conversion of derivative security | 60K shares |
Open market or private sale | 101K shares |
---|---|
Bona fide gift | 8K shares |